Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-1084 + pembrolizumab + carboplatin + pemetrexed
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
MK-1084 + pembrolizumab + carboplatin + pemetrexed is an investigational **four-drug combination regimen** under clinical development, primarily for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with KRAS G12C mutations and high PD-L1 expression. **MK-1084** is a selective oral KRAS G12C inhibitor that targets tumor cells harboring this mutation, disrupting KRAS-mediated oncogenic signaling. **Pembrolizumab** (KEYTRUDA) is a monoclonal antibody acting as a PD-1 immune checkpoint inhibitor, enhancing antitumor immune response. **Carboplatin** and **pemetrexed** are chemotherapeutics: carboplatin is a platinum agent causing DNA crosslinking and apoptosis, while pemetrexed is an antifolate that interferes with folate-dependent enzymes involved in DNA synthesis. The combination leverages targeted therapy, immunotherapy, and chemotherapy for synergistic antineoplastic effects[1][2][4][5][6][7].
- Other names
- pembrolizumabcarboplatinpemetrexed
02
Targets
DNAKRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on MK-1084 + pembrolizumab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-1084 + pembrolizumab + carboplatin + pemetrexed.